Who Is Buying Johnson & Johnson? Hedge Fund Activity in 2026

Johnson & Johnson is the world's largest healthcare products company and one of only two US corporations with a AAA credit rating (the other being Microsoft). Following the 2023 spinoff of its consumer health division (now Kenvue), J&J has transformed into a focused pharmaceuticals and medical devices powerhouse. For institutional investors, JNJ represents stability, innovation, and one of the most reliable dividend growth records in corporate history.

Here's what the latest 13F filings tell us about hedge fund activity in JNJ.

Johnson & Johnson at a Glance

Post-Kenvue spinoff, J&J is a leaner, more focused company. Its Innovative Medicine (pharmaceuticals) and MedTech (medical devices) segments now drive all revenue, providing a clearer growth profile for institutional investors.

Who's Buying Johnson & Johnson in 2026?

Based on Q4 2025 13F filings, several major hedge funds have been accumulating JNJ shares:

1. Bridgewater Associates

Bridgewater increased its J&J position by 40% in Q4 2025, now holding approximately $2.6 billion. The macro fund views JNJ as an ideal defensive holding — a company that generates stable earnings in any economic environment while paying a growing dividend.

2. Capital Research Global Investors

Capital Research added approximately 14 million shares of JNJ, making it one of the fund's largest healthcare holdings. The long-term investor values J&J's pharmaceutical pipeline and its ability to compound earnings over decades.

3. Berkshire Hathaway (Warren Buffett)

Berkshire maintained and modestly increased its JNJ position, now worth approximately $1.8 billion. Buffett appreciates J&J's predictable cash flows and its status as a "forever company" with a 62-year streak of consecutive dividend increases.

4. Citadel Advisors (Ken Griffin)

Citadel added roughly $1.5 billion in JNJ shares during Q4 2025, with the fund using J&J as a defensive offset to its larger technology-heavy portfolio.

5. Viking Global Investors (Andreas Halvorsen)

Viking Global initiated a new $1.3 billion position in J&J, with healthcare analysts highlighting the strength of the company's immunology and oncology drug pipelines.

6. BlackRock (Active Strategies)

Beyond passive holdings, BlackRock's active strategies increased their JNJ exposure by approximately $2.1 billion, viewing the stock as undervalued following a period of litigation-related overhang.

Who's Reducing JNJ?

1. Tiger Global Management

Tiger Global exited its JNJ position entirely in Q4 2025, consistent with the fund's shift away from defensive names toward higher-growth technology stocks.

2. Two Sigma Investments

Two Sigma trimmed its J&J position by approximately 18%, with quantitative models potentially favoring faster-growing healthcare names like UnitedHealth.

Why Hedge Funds Like Johnson & Johnson

1. Pharmaceutical Pipeline Strength J&J's Innovative Medicine segment has delivered multiple blockbuster drugs, including Darzalex (multiple myeloma), Stelara (immunology), Tremfya (psoriasis), and Tecvayli (oncology). The company has over 50 programs in late-stage development, providing visibility into future revenue growth.

2. MedTech Leadership J&J's MedTech division is the largest medical devices company globally, with leading positions in orthopedics, surgery, and interventional solutions. The aging global population drives structural demand growth for joint replacements, surgical robots, and cardiovascular devices.

3. Dividend Aristocrat J&J has increased its dividend for 62 consecutive years, one of the longest streaks in corporate America. At a ~3.1% yield, the stock provides meaningful income, and hedge funds focused on total return value the predictability of this income stream.

4. Litigation Resolution The resolution of talc-related lawsuits, which had weighed on J&J's stock for years, removes a significant overhang. Hedge funds that waited on the sidelines during the litigation uncertainty are now entering the stock at what they view as a discounted valuation.

5. AAA Balance Sheet J&J's AAA credit rating provides unmatched financial flexibility. The company can fund acquisitions, R&D, and capital returns without concern about borrowing costs or financial stress, making it one of the safest large-cap stocks available.

Recent Institutional Moves

The 13F data for Johnson & Johnson shows a notable shift toward accumulation:

• New positions opened: Approximately 220 funds initiated new JNJ positions in Q4 2025
• Positions increased: Roughly 620 funds added to existing holdings
• Positions reduced: About 340 funds trimmed their stakes
• Positions exited: Approximately 160 funds closed their JNJ positions entirely

The most significant trend is value-oriented and income-focused hedge funds returning to J&J after a multi-year absence caused by litigation uncertainty. With the talc overhang largely resolved and pharmaceutical revenue growing, institutional sentiment has turned decidedly positive.

How to Track Johnson & Johnson Institutional Activity with Freenance

Freenance's Smart Money Tracker makes it easy to monitor institutional moves in J&J:

• Complete 13F aggregation showing every institutional holder of JNJ
• Quarterly change tracking that highlights significant buys, sells, and new positions
• Long-term ownership trends to see how institutional sentiment has shifted post-Kenvue spinoff
• Watchlist alerts when major funds adjust their J&J holdings

Stay informed on institutional activity in the world's largest healthcare company.

👉 Try Freenance's Smart Money Tracker

Frequently Asked Questions

How many hedge funds own Johnson & Johnson?

As of Q4 2025, approximately 4,300 institutional investors report holding JNJ in their 13F filings. Among hedge funds specifically, roughly 820+ hold JNJ positions. The stock's appeal to both growth and income investors ensures a diverse institutional shareholder base.

Is JNJ still a good dividend stock?

With 62 consecutive years of dividend increases and a ~3.1% yield, JNJ remains one of the premier dividend growth stocks in the market. The post-Kenvue payout ratio is comfortable at roughly 40% of earnings, suggesting ample room for future increases. Most hedge funds holding JNJ factor the dividend into their total return thesis.

How did the Kenvue spinoff affect JNJ?

The spinoff of Kenvue (consumer health brands like Tylenol, Band-Aid, Neutrogena) in 2023 transformed J&J into a pure-play pharmaceutical and medical devices company. Most hedge funds view this positively — the remaining business has higher margins, faster growth, and greater R&D-driven value creation potential.

What are the main risks for JNJ investors?

Key institutional concerns include: patent cliffs (Stelara biosimilar competition beginning in 2025), pharmaceutical pricing regulation, pipeline execution risk (late-stage clinical trial failures), and potential for additional litigation in other product areas. However, J&J's diversified portfolio and financial strength mitigate these risks.

Related Articles

• Who Is Buying UnitedHealth? Hedge Fund Activity in 2026
• Who Is Buying Berkshire Hathaway? Hedge Fund Activity in 2026
• Berkshire Hathaway — Warren Buffett's Fund Profile & 13F Portfolio
• Bridgewater Associates — Ray Dalio's Fund Profile & 13F Portfolio
• Citadel Advisors — Ken Griffin's Multi-Strategy Fund Profile
• BlackRock — Profile of the World's Largest Asset Manager
• Capital Research Global Investors — Profile of the American Funds Powerhouse
• Viking Global Investors — Profile of Andreas Halvorsen's Fund